Amphastar Pharmaceuticals Inc (AMPH) Stock
Key stats
- Market cap
- $1.22B
- Price / Earnings ratio
- 12.5x
- EPS (TTM)
- $2.25
- Volume
- Loading
- 52-week high
- $31.00
- 52-week low
- $16.65
Source: third-party data provider, as of November 13, 2026
Compare with AMPH
Recent news
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
AMPH
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
AMPH
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
AMPH
New Strong Sell Stocks for August 14th
New Strong Sell Stocks for August 14th
AMPHNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 63.15
- MACD 12/26/9
- 0.92
- EMA 9 of MACD
- 0.74
- MACD histogram
- 0.18
- SMA 50
- $25.74
- Price above SMA 50
- EMA 50
- $25.72
- Price above EMA 50
- SMA 200
- $22.33
- Price above SMA 200
- EMA 200
- $23.91
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
AMPHShould Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
AMPH3 Generic Drug Stocks to Watch Amid Improving Industry Trends
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
AMPHNew Strong Sell Stocks for August 14th
New Strong Sell Stocks for August 14th
AMPH
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
AMPH
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates
AMPH
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
AMPH
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
AMPH
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
AMPH
New Strong Sell Stocks for June 23rd
New Strong Sell Stocks for June 23rd
AMPHNews tone: automated (AI) classification of the article's content, not a price prediction.
About Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Yongfeng Zhang Ph.D. | Co-Founder, President, CEO, Chief Scientific Officer & Director | 1947 |
| Dr. Ziping Luo Ph.D. | Chairman of the Board, Chief Scientist & COO | 1950 |
| Mr. William J. Peters M.B.A. | CFO, Executive VP of Finance, Treasurer & Director | 1968 |
| Mr. Jacob Liawatidewi M.B.A. | Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director | 1974 |
| Mr. Rong Zhou M.S. | Senior EVP of Production & EVP of Scientific Affairs | 1959 |
| Mr. Dan Dischner M.B.A. | Senior Vice President of Human Resources & Corporate Communication | — |
| Tony Marrs M.B.A., M.P.H., M.S. | Executive VP of Regulatory Affairs & Clinical Operations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 63.15
- MACD 12/26/9
- 0.92
- EMA 9 of MACD
- 0.74
- MACD histogram
- 0.18
- SMA 50
- $25.74
- Price above SMA 50
- EMA 50
- $25.72
- Price above EMA 50
- SMA 200
- $22.33
- Price above SMA 200
- EMA 200
- $23.91
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $23.00
- Average
- $24.00
- High
- $25.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -7.5 | +17.3 | ||||||||||
| 2022 | +0.1 | +12.3 | +30.9 | -5.2 | +5.2 | -7.6 | +5.8 | -20.0 | -5.4 | +8.8 | -5.7 | -6.7 |
| 2023 | +7.3 | +4.1 | +2.6 | -6.2 | +19.0 | +27.3 | +5.3 | -12.1 | -15.7 | -1.0 | +23.9 | +6.8 |
| 2024 | -14.3 | -12.9 | -5.0 | -5.0 | +0.6 | -5.3 | +0.5 | |||||
| 2026 | -27.7 | -6.8 | +8.5 | -13.8 | +9.6 | -0.8 | +11.4 | +12.4 | +9.3 | +5.8 |
